Presentation (CTI)

OBJECTIVES: Obesity and overweight pose a significant global health and economic burden. Lifestyle interventions are recommended as first-line treatments, and personalization of those interventions is potentially more effective than one-size-fits-all interventions. However, the cost-effectiveness remains unclear. The aim of this review is to assess the methodology, findings and quality of existing cost-effectiveness analyses evaluating personalized lifestyle interventions in adult obesity or overweight.
METHODS: MEDLINE, Embase, Web of Science and Scopus were systematically searched in May 2025. Full economic evaluations of personalized lifestyle interventions in adult obesity or overweight were included, with no restriction on publication date. Studies were categorized by personalization level, i.e., conventional personalization (level 1), phenotype-based (level 2), and genetics/omics-based (level 3). The reporting quality was assessed using the CHEERS 2022 Checklist.
RESULTS: From 15,385 records screened, 18 studies met inclusion criteria. Most studies evaluated conventional personalization (level 1, n=11, 61%), few addressed phenotype-based personalization (level 2, n=5, 28%), and only two studies evaluated genotype/omics-based interventions (level 3, n=2, 11%). Within-trial study designs predominated over model-based. Methodological heterogeneity and variable reporting quality were observed.
CONCLUSIONS: The scarcity of cost-effectiveness analyses evaluating advanced personalized lifestyle interventions highlights a critical knowledge gap. Future research should prioritize high-quality health economic evaluations of advanced personalization strategies to inform resource allocation in the prevention and management of adult obesity and overweight.